Therapeutic ultrasound affects IGF-1 splice variant expression in human skeletal muscle

What Was Tested

The paper reports a study of IGF-1 LR3, published as a randomized controlled trial.

This study was undertaken to examine the 3 known splice variants of the IGF-1 gene in human skeletal muscle after damage and TUS treatment.

Why It Was Studied

However, these effects have not been verified in humans.

Who Took Part

By PubMed's age tags, the people studied were teenagers, young adults and adults, men only.

Sixteen healthy men (18-29 years of age), physically active, were randomized to either a control (CON) or experimental group (EXP).

Bilateral muscle biopsy samples were taken from all participants, 6 hours after TUS.

How the Study Was Run

In design terms this was a randomized study.

Random assignment meant chance, not the researchers, decided who got IGF-1 LR3 and who got the comparison, which limits bias.

The EXP group underwent 200 lengthening contractions (muscle damage) of the quadriceps of both legs, 48 hours before TUS.

Both groups received TUS, delivered for 10 minutes on a standardized area of the vastus lateralis of only 1 leg (1.0 MHz, 1.5 W/cm(2)).

Total RNA was extracted, and quantitative real-time polymerase chain reaction conducted for each IGF-1 splice variant.

What Was Measured

The subject headings attached to it are Creatine Kinase, Gene Expression, Insulin-Like Growth Factor I, Muscle Strength, Protein Isoforms, Quadriceps Muscle and Ultrasonic Therapy.

What This Means in Plain Language

The paper is a randomized study of IGF-1 LR3.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2011 (The American journal of sports medicine), a journal based in United States.

More context: the IGF-1 LR3 compound page, all human trials.